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Andrew McCulloch – University of California, SanDiego, USAStudies in non-human primates (NHPs) have been
crucial for our understanding of measles as a high
impact viral disease of humans. Over a century ago,
inoculations of NHPs with ﬁltered secretions from
measles patients ﬁrst identiﬁed a virus as the causative
agent of this disease. In the 1960s, studies in NHPs with
measles virus isolates passaged in vitro provided the
basis for live-attenuated measles virus vaccines, which
became one of the most successful medical interven-
tions in history. More recently, experimental infections
of NHPs have provided critical contributions to our
understanding of the tropism and pathogenesis of mea-
sles virus. This review brieﬂy highlights some of the
lessons learned from NHP models of measles virus
infection.
Measles
Before the introduction of vaccination, measles was a com-
mon infectious disease that caused frequent outbreaks asso-
ciated with high morbidity and mortality [1,2]. Measles
usually manifests itself as childhood disease in densely pop-
ulated areas, but non-immune humans of all ages can develop
the disease [3]. The causative agent, measles virus (MeV), is
one of the most contagious pathogens of humans, and is
spread by airborne transmission [4]. The virus is a member ofPlease cite this article in press as: de RL. Measles: What we have learned from non-hum
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the family Paramyxoviridae, genus Morbillivirus and contains a
non-segmented single stranded RNA genome of negative
polarity, encapsidated by the viral nucleoprotein and sur-
rounded by a lipid envelope. Measles has an incubation
period of approximately two weeks, after which patients
develop cough, fever and a typical maculopapular skin rash.
However, hallmark of measles is the transient but severe
immune suppression that develops during the resolution of
disease and can persist for over two years, resulting in in-
creased susceptibility to opportunistic infections [5,6]. This
often leads to complications such as pneumonia or severe
diarrhea, which are a major cause of measles-associated mor-
tality. Introduction of safe and effective live-attenuated mea-
sles virus vaccines has strongly reduced global childhood
mortality [6]. Indeed, development of today’s MeV vaccines
has depended strongly on NHP studies [7,8]. However, MeV is
still estimated to cause almost a hundred thousand deaths
each year, all of which are vaccine-preventable [9].
Measles pathogenesis
Although MeV is transmitted via the respiratory route, its
pathogenesis differs from most other respiratory viruses. The
virus causes a systemic disease, involving infection of various
cell types mediated by at least two cellular receptors. In 2000,
CD150 (or SLAM-F1) was identified as a cellular receptor foran primate models, Drug Discov Today: Dis Model (2018), https://doi.org/10.1016/j.
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(or PVRL4) as a second cellular receptor [11,12]. CD150 is
expressed by subsets of myeloid and lymphoid immune cells.
Nectin-4 is an adherens junction protein that is expressed by
keratinocytes and differentiated respiratory epithelial cells,
but exclusively at their basolateral side. In addition, it has
been shown that the C-type lectins DC-SIGN and Langerin,
expressed by dendritic cells (DCs) and Langerhans cells, can
serve as attachment receptors for MeV. Although these do not
mediate viral entry, they strongly enhance virus transmission
from DCs to CD150-positive lymphocytes [13,14]. It is now
thought that MeV enters the host by initial infection of
myeloid cells (macrophages and DCs) in the respiratory tract,
which serve as ‘‘Trojan horses’’ to transmit MeV to CD150-
positive T- and B-lymphocytes in the draining lymphoid
tissues. These MeV-infected lymphocytes subsequently me-
diate a cell-associated viremia, resulting in dissemination to
virtually all peripheral lymphoid tissues, including local DCs
and lymphocytes in the submucosa of the respiratory epithe-
lium. These cells transmit the virus to respiratory epithelial
cells through basolateral infection, mediated by nectin-4.
Infection of epithelial cells results in apical budding of novel
virus particles, concurrent with epithelial damage that
induces cough, which in turn supports airborne transmission
of MeV to the next host [15].
Measles animal models
A variety of animal species has been considered as model of
MeV infection. Small laboratory animals are in most cases not
susceptible to MeV infection, with the exception of cotton
rats [16]. However, MeV infection of cotton rats does not
recapitulate the complex pathogenesis of measles as seen in
humans. Several transgenic rodent models have been devel-
oped, but these required both expression of MeV receptors
and knockout of type 1 interferon responses to support MeV
entry and replication [17]. Therefore, two options remain:
infections with animal morbilliviruses in their natural host
species (e.g. canine distemper virus infection of ferrets
[18,19]) or experimental infection of NHPs with MeV
[8,20]. Whereas canine distemper virus was first identified
in dogs, it can infect virtually all carnivores. Similarly, MeV
should be considered as a virus that infects primates rather
than a virus that exclusively infects humans. However, due to
the fact that MeV exclusively infects previously unexposed
primates, the virus can only maintain endemic circulation in
populations of more than 250,000 individuals [21]. As free-
ranging NHP populations are well below this size, MeV does
not circulate among NHPs under natural conditions but
exclusively causes outbreaks after contact of NHPs with
humans [8]. Experimental infections of NHPs have been
essential for our understanding of the tropism of both
wild-type and vaccine MeV strains, the pathogenesis ofPlease cite this article in press as: de RL. Measles: What we have learned from non-hum
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of MeV as vaccine vector or oncolytic virus.
Measles virus tropism in NHPs
The incubation period between MeV infection and onset of
skin rash is on average two weeks [4]. Therefore, studying
early aspects of the pathogenesis of measles in humans has
been difficult. The development of recombinant MeV strains
that express luminescent or fluorescent proteins, combined
with the large spectrum of antibodies available for specific
phenotyping NHP cell types by flow cytometry and/or histol-
ogy, has enabled accurate tropism studies in NHPs that
elucidated MeV entry, pathogenesis, dissemination and im-
mune suppression (as outlined in paragraph 2 of this review)
[20,22–27]. In addition, generation of so called ‘‘receptor-
blind’’ recombinant viruses, unable to bind to either CD150
or nectin-4, has helped elucidate the roles of both cellular
entry receptors in NHPs [28–30]. More recently, tropism
studies were conducted with the live-attenuated MeV vaccine
strain Edmonston-Zagreb expressing green fluorescent pro-
tein, which was found to predominantly target myeloid
antigen-presenting cells in the muscle of NHPs after intra-
muscular injection [31]. This recombinant vaccine virus was
also used to study tropism and immunogenicity upon respi-
ratory vaccination, demonstrating that the vaccine virus
needed to be delivered to the lower respiratory tract for
optimal immunogenicity and induction of protective immu-
nity [32].
Measles immune suppression in NHPs
As described above, one of the most important sequelae of
measles is immune suppression, significantly contributing to
measles morbidity and mortality. Interestingly, measles is
associated with simultaneous immune suppression and im-
mune activation [33]: despite the fact that MeV causes lym-
phopenia and reduces host resistance to other infections, it
also induces a strong immune response to itself resulting in
life-long protection from measles. This phenomenon is com-
monly referred to as the ‘‘measles paradox’’. Studies of MeV
infection in NHPs elucidated a tropism for specific lympho-
cyte subsets, which resulted in a novel model for measles
immune suppression that is fully compatible with the mea-
sles paradox. Infection of specific CD150-positive lympho-
cyte subsets resulted in a partial depletion of memory
lymphocyte subsets, leading to ‘‘immune amnesia’’. This
depletion is masked by the rapid proliferation of MeV-specific
lymphocytes, which mediate clearance of MeV-infected cells
but cannot protect the host from other infections [34,35].
This model also explains the fact that measles immune
suppression can last for several weeks to months after mea-
sles, whereas measles lymphopenia is usually resolved within
a week after recovery. Additional support for this model was
obtained from epidemiological studies in humans, thatan primate models, Drug Discov Today: Dis Model (2018), https://doi.org/10.1016/j.
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a period of more than two years [6]. Whether or not the
prolonged persistence of MeV RNA in lymphocytes, another
phenomenon which has been detected in NHPs, contributes
to long-term measles sequelae remains to be determined
[36,37].
Measles vaccination in NHPs
In addition to elucidating the tropism of the existing live-
attenuated MeV vaccine, NHPs have also been used to evalu-
ate new generation MeV vaccines and novel routes of MeV
vaccination [38,39]. In addition to needle-free vaccination
via the respiratory route [40,41] (referred to in paragraph 4),
another promising alternative for the use of hypodermic
needles to deliver the live-attenuated MeV vaccine are micro-
needle patches [42,43]. These micron-scale dissolvable poly-
meric needles were formulated to encapsulate the standard
live-attenuated MeV, and were used for intradermal vaccina-
tion without the requirement of vaccine reconstitution. Stud-
ies in NHPs have provided proof of principle of this approach,
supporting further clinical development.
It is important to note that live-attenuated MeV strains are
not only used for measles vaccination, but are also being
developed as recombinant vectors for delivery of other anti-
gens [44]. Several candidates have been evaluated in NHPs,
including MeV-based candidate vaccines against Epstein–
Barr virus, hepatitis B virus, HIV-1, human papilloma virus,
Nipah virus and West Nile virus, some of which have pro-
gressed to clinical testing in humans (Chikungunya virus and
Zika virus [45,46]).
Measles-based oncolytic virotherapy
In addition to playing a role as vaccine vector, an alternative
application of live-attenuated MeV vaccines that has emerged
relatively recently is oncolytic virotherapy [47,48]. The ma-
jority of these studies is performed in mouse models
engrafted with human tumours, which means that the virus
usually has limited potential to infect the host and mainly
targets the tumour. Although in this arena efficacy studies are
not likely to be performed in NHPs, safety studies may be of
crucial importance for further development of these strate-
gies [49].
Replacement, reduction and reﬁnement
Implementation of the principles of the 3Rs (replacement,
reduction and refinement) is of crucial importance for all
studies in which animal models are considered, but may be
even more critical when considering NHP studies. Many
aspects of virus tropism and replication can be studied in
vitro, using either immortalized cell lines, primary cells, orga-
noids or ex vivo tissue culture. However, as described above
morbilliviruses have a complex pathogenesis, which involves
many organs and cell types and directly interferes with thePlease cite this article in press as: de RL. Measles: What we have learned from non-hum
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the use of animals will be impossible. Reduction strategies
aim to minimize the number of animals per experiment,
which can be achieved by improving study design and
focusing on the robustness and reproducibility of the experi-
ments. The use of recombinant viruses that express fluores-
cent reporter proteins has strongly contributed to this goal.
Finally, refinement (improving animal welfare) is of crucial
importance. This involves the best possible housing and
care, and implementation of optimal in vivo technologies,
including adequate anesthesia and analgesia. These strate-
gies are further supported by the fact that an increasing
number of scientific journals required studies to be compli-
ant with the ARRIVE guidelines for reporting of research
using animals [50].
Concluding remarks
The scientific committee on Health, Environmental and
Emerging Risks (SCHEER) has recently updated its opinion
on ‘‘The need for non-human primates in biomedical re-
search, production and testing of products and devices’’
[51]. The opinion focuses on approaches aimed at implemen-
tation of the 3Rs in studies that use NHPs. Although the
ultimate objective remains phasing out the research use of
NHPs in Europe, the Opinion concluded that NHPs remain
indispensable for particular types of research for now. Among
these are the study of measles pathogenesis and possible
applications of recombinant MeV for innovative develop-
ments for prevention (vaccines against MeV and other
agents) and therapeutics (e.g. oncolytic virotherapy).
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